EMAIL
info@prfbd.org
Call Now
+880 255 035 439
Ongoing PROJECTS
- 1. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥ 60 Years of Age
- 2. The WHO Antenatal Corticosteroids for Improving Outcomes in Preterm Newborns (ACTION) Trials--ACTION III: A multi-country, multi-centre, three-arm, parallel group, double-blind, placebo-controlled, randomized trial of two doses of antenatal corticosteroids for women with a high probability of birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes.
- 3. Using ongoing newborn intervention trials to obtain additional data critical to maternal, fetal and newborn health in a harmonized way in Sylhet District, Bangladesh: the AMANHI (Alliance for Maternal and Newborn Health Improvement) cohort study.
- 4. A Phase III, randomized, double-blind, placebo-controlled multi-country study to demonstrate efficacy of a single dose of unadjuvanted RSV Maternal vaccine, administered IM to pregnant women 18 to 49 years of age, for prevention of RSV associated LRTI in their infants up to 6 months of age.
- 5. Breastfeeding Counselling and Management of Growth in early infancy (Nutritional management of growth faltering in infants aged under six months in Asia and Africa: An individually randomized trial)
- 6. Implementation Research to Scale-up and Evaluate the Impact of Antenatal Corticosteroids on Preterm Newborn Outcomes
- 7. Integrating immediate Kangaroo Mother Care into district hospitals with level 2 NICU: Implementation Research
- 8. Field-testing and validation of the Global Scale for Early Development (GSED) for 0- to 3-year-old children
- 9. The E-Patient Quality Improvement & Standardization—EQIS—Platform to Improve Clinical Care in Bangladesh
- 10. Global Platform for Maternal and Newborn Health in Bangladesh
- 11. Antenatal dexamethasone for preterm birth and long-term health outcomes in children: a pilot follow-up cohort study of ACTION-I trial participants in Sylhet, Bangladesh